Marwan Ma'ayeh1, Kara M Rood2, Douglas Kniss2, Maged M Costantine2. 1. Division of Maternal Fetal Medicine, Department of Obstetrics & Gynecology, The Ohio State University College of Medicine, 395 W 12th Avenue, Columbus, OH, 43210, USA. Marwan.Ma'ayeh@osumc.edu. 2. Division of Maternal Fetal Medicine, Department of Obstetrics & Gynecology, The Ohio State University College of Medicine, 395 W 12th Avenue, Columbus, OH, 43210, USA.
Abstract
PURPOSE OF REVIEW: To review the rationale and biological plausibility and discuss the current research on novel interventions for the prevention of preeclampsia. RECENT FINDINGS: Preeclampsia affects up to 8% of pregnancies worldwide and remains a major cause of maternal and neonatal morbidity and mortality. Multiple medications have been investigated or repurposed as potential effective interventions for preeclampsia prevention. Aspirin is currently the only drug for which there is some evidence of benefit for preeclampsia prevention, and its use is recommended by professional societies for pregnancies at risk. Statins have shown promise for prevention of preeclampsia in animal models and human pilot studies, without any trend or concerns for safety signals or teratogenicity. The use of metformin has also gained popularity in experimental studies, but observations from randomized clinical trials were not consistent on its utility as a possible intervention for preeclampsia prevention. While initial studies evaluating esomeprazole were promising, randomized trials failed to show benefit. Contemporary research shows exciting new opportunities for prophylactic treatment for preeclampsia, to prevent this debilitating and life-threatening disease.
PURPOSE OF REVIEW: To review the rationale and biological plausibility and discuss the current research on novel interventions for the prevention of preeclampsia. RECENT FINDINGS: Preeclampsia affects up to 8% of pregnancies worldwide and remains a major cause of maternal and neonatal morbidity and mortality. Multiple medications have been investigated or repurposed as potential effective interventions for preeclampsia prevention. Aspirin is currently the only drug for which there is some evidence of benefit for preeclampsia prevention, and its use is recommended by professional societies for pregnancies at risk. Statins have shown promise for prevention of preeclampsia in animal models and human pilot studies, without any trend or concerns for safety signals or teratogenicity. The use of metformin has also gained popularity in experimental studies, but observations from randomized clinical trials were not consistent on its utility as a possible intervention for preeclampsia prevention. While initial studies evaluating esomeprazole were promising, randomized trials failed to show benefit. Contemporary research shows exciting new opportunities for prophylactic treatment for preeclampsia, to prevent this debilitating and life-threatening disease.
Authors: Jillian T Henderson; Evelyn P Whitlock; Elizabeth O'Connor; Caitlyn A Senger; Jamie H Thompson; Maya G Rowland Journal: Ann Intern Med Date: 2014-05-20 Impact factor: 25.391
Authors: Karin A Fox; Monica Longo; Esther Tamayo; Talar Kechichian; Egle Bytautiene; Gary D V Hankins; George R Saade; Maged M Costantine Journal: Am J Obstet Gynecol Date: 2011-06-29 Impact factor: 8.661
Authors: B M Sibai; S N Caritis; E Thom; M Klebanoff; D McNellis; L Rocco; R H Paul; R Romero; F Witter; M Rosen Journal: N Engl J Med Date: 1993-10-21 Impact factor: 91.245